Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

314 results about "Polycyclic compound" patented technology

In the field of organic chemistry, a polycyclic compound is an organic compound featuring several closed rings of atoms, primarily carbon. These ring substructures include cycloalkanes, aromatics, and other ring types. They come in sizes of three atoms and upward, and in combinations of linkages that include tethering (such as in biaryls), fusing (edge-to-edge, such as in anthracene and steroids), links via a single atom (such as in spiro compounds), bridged compounds, and longifolene. Though poly- literally means "many", there is some latitude in determining how many rings are required to be considered polycyclic; many smaller rings are described by specific prefixes (e.g., bicyclic, tricyclic, tetracyclic, etc.), and so while it can refer to these, the title term is used with most specificity when these alternative names and prefixes are unavailable.

Condensed ring compound as well as preparation method and medical application thereof

The invention relates to a fused ring compound, a preparation method thereof and application of the fused ring compound in medicine. Specifically, the invention relates to a fused ring compound as shown in a general formula (IN), a preparation method thereof, a pharmaceutical composition containing the compound and application of the fused ring compound as a therapeutic agent, in particular to application of the fused ring compound in preparation of drugs for inhibiting KRAS G12D. Wherein each group in the general formula (IN) is as defined in the specification. # imgabs0 #
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Condensed ring compound as well as preparation method and medical application thereof

The invention relates to a fused ring compound, a preparation method thereof and application of the fused ring compound in medicine. Specifically, the invention relates to a fused ring compound as shown in a general formula (IN), a preparation method thereof, a pharmaceutical composition containing the compound and application of the fused ring compound as a therapeutic agent, in particular to application of the fused ring compound in preparation of drugs for inhibiting KRAS G12D. Wherein each group in the general formula (IN) is as defined in the specification. # imgabs0 #
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Pyrimidine-containing polybasic ring derivative inhibitor as well as preparation method and application thereof

The invention relates to a pyrimidine-containing polybasic ring derivative inhibitor as well as a preparation method and application thereof. In particular, the invention relates to a pyrimidine-containing multi-element fused ring compound or a stereoisomer thereof, a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound or the stereoisomer thereof in preparation of drugs for treating cancers and other related diseases.
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1

Polycyclic compound containing triphenyl silicon and polyalkyl substituent and organic electroluminescent device containing polycyclic compound

The invention belongs to the technical field of OLEDs, and provides a polycyclic compound containing triphenyl silicon and a polyalkyl substituent group and an organic electroluminescent device containing the polycyclic compound. The structural general formula of the polycyclic compound is as shown in formula I in the specification. Benzofuran with higher electronegativity is introduced to a ring structure composed of nitrogen atoms and boron atoms, triphenyl silicon is introduced to the para-position of boron, and the synergistic effect of benzofuran and triphenyl silicon can significantly enhance the multiple resonance of a light-emitting core and reduce vibration relaxation. Due to simultaneous use of the benzofuran and the triphenyl silicon, the problems of vibration relaxation increase, spectrum widening and the like caused by introduction of the polyalkyl substituent are remarkably improved, the luminous efficiency of the material is remarkably improved, and the color purity is improved, so that the requirement of BT.2020 wide color gamut display standard on a luminescent spectrum is met. I
Owner:SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO LTD

Polycyclic compound containing benzene ring as well as pharmaceutical composition and application thereof

The invention discloses a polycyclic compound containing a benzene ring as well as a pharmaceutical composition and application thereof. Specifically provided is a compound represented by formula (I-E) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the structure is novel; (2) the compound has a good retarding effect on the activity of a NaV1.8 channel; and (3) the method has good selectivity on other subtypes of Nav (such as Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7 and Nav1.9), and is high in safety. # imgabs0 #
Owner:WUHAN XIRUI PHARMACEUTICAL TECHNOLOGY CO LTD

Polycyclic compound, preparation method therefor, and pharmaceutical use thereof

The present disclosure relates to a polycyclic compound, a preparation method therefor, and the pharmaceutical use thereof. Specifically, the present disclosure relates to a polycyclic compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a therapeutic agent, in particular, the use as an RAS inhibitor and the use in the preparation of a drug for treating and / or preventing RAS-mediated or dependent diseases or conditions, wherein each group in general formula (I) is as defined in the description.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Organic light-emitting device

The present invention relates to an organic light-emitting device employing, as a host of a light emission layer, an anthracene derivative compound having a characteristic structure by introduction of a benzofuran structure into the anthracene backbone, and as a dopant of the light emission layer, a polycyclic compound having a characteristic structure. The organic light-emitting device according to the present invention is an organic light-emitting device with significantly improved external quantum efficiency and can be advantageously utilized not only for lighting devices but also for various display devices, such as flat, flexible, and wearable displays.
Owner:SFC CO LTD

Polycyclic compound and application thereof

The invention provides a compound as shown in a formula (I), and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. As a GLP-1R agonist, the compound and the pharmaceutical composition thereof can be used for preparing drugs for treating and / or preventing diseases mediated by GLP-1R. # imgabs0 #
Owner:CSPC BAIKE (SHANDONG) BIO-PHARMACEUTICAL CO LTD

Polycyclic compound containing benzene ring as well as pharmaceutical composition and application thereof

The invention discloses a polycyclic compound containing a benzene ring as well as a pharmaceutical composition and application thereof. Specifically provided is a compound represented by formula (I-C) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the structure is novel; (2) the compound has a good retarding effect on the activity of a NaV1.8 channel; and (3) the method has good selectivity on other subtypes of Nav (such as Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7 and Nav1.9), and is high in safety. # imgabs0 #
Owner:WUHAN XIRUI PHARMACEUTICAL TECHNOLOGY CO LTD

Organic electroluminescence device and polycyclic compound for organic electroluminescence device

An organic electroluminescence device includes: a first electrode; a second electrode disposed on the first electrode; and at least one organic layer disposed between the first electrode and the second electrode. wherein the at least one organic layer includes a polycyclic compound having a core structure including a n,n′-bicarbazole moiety and, outside the core structure, at least one optionally substituted carbazole group, and the substituted or unsubstituted carbazole groups of the core structure substituted at any one among carbon atoms at position n±1 of the n,n′-bicarbazole moiety, and any one among carbon atoms at position n′±1 of the n,n′-bicarbazole moiety, respectively; and n and n′ are, independently from one another, integers of 1 to 4 (where n±1 and n′±1 are not 0).
Owner:SAMSUNG DISPLAY CO LTD

Substituted polycyclic compound

A substituted polycyclic compound having biological inhibitory activity represented by formula (II), a preparation method therefor, and a use thereof. The use comprises a use of the compound of formula (II) in the preparation of a drug for treating MLL-related diseases. In the preparation process, the compound is obtained by means of a series of reactions such as substitution, cyclization, reduction, and deprotection.
Owner:SHOUYAO HOLDINGS (BEIJING) CO LTD

Method for semi-solid-phase synthesis of polycyclic compound and intermediate

The invention relates to a method for semi-solid-phase synthesis of a polycyclic compound and an intermediate, a long chain is synthesized through solid phase, then two-step ring closing is performed to form a key intermediate, and simple derivation is performed on the basis of the key intermediate to obtain a PCSK9 antagonist compound. According to the invention, starting materials for solid-phase synthesis are selected, steric hindrance is effectively avoided, and solid-phase reaction and subsequent liquid-phase correlation cyclization can be smoothly carried out, so that the yield is improved, and the cost is reduced.
Owner:SHANDONG UNIV +1

Synthesis method of polycyclic compound and intermediate

The invention relates to a synthesis method of a polycyclic compound and an intermediate, a long chain is synthesized firstly, then two-step ring closing is performed to form a key intermediate, and simple derivation is performed on the basis of the key intermediate to obtain a PCSK9 antagonist compound. According to the invention, a ring closing route and an intermediate are optimized, and the ring closing yield is improved.
Owner:SHANDONG UNIV +1

Condensed polycyclic compound, preparation method thereof and application of fused polycyclic compound in medicine

The invention relates to a fused polycyclic compound, a preparation method thereof and application of the fused polycyclic compound in medicine. Specifically, the invention relates to a condensed polycyclic compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, the invention also relates to the use thereof as an Apelin receptor agonist, in particular as an Apelin receptor agonist and in the preparation of a medicament for the treatment and / or prevention of Apelin receptor mediated or dependent diseases or conditions. # imgabs0 #
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Light emitting device

A light emitting device according to an embodiment includes a first electrode and a second electrode facing the first electrode, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one among the plurality of organic layers includes a fused polycyclic compound represented by Formula 1 below, thereby showing improved emission efficiency.
Owner:SAMSUNG DISPLAY CO LTD

Polycyclic compound as well as preparation method and medical application thereof

The invention relates to a polycyclic compound, a preparation method thereof and application of the polycyclic compound in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method of the polycyclic compound, a pharmaceutical composition containing the polycyclic compound and application of the polycyclic compound as a therapeutic agent, especially application of the polycyclic compound as a BTK inhibitor or degradation agent and application of the polycyclic compound in preparation of drugs for treating and / or preventing BTK-mediated or dependent diseases or symptoms. Wherein each group in the general formula (I) is defined in the specification.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Polycyclic compound, pharmaceutical composition thereof, and use thereof

The present invention provides a polycyclic compound, a pharmaceutical composition thereof, and a use thereof. The polycyclic compound of the present invention has a structure as shown in formula A, wherein the definitions of R1-R6, ring A-ring E, L, n, m, q, and t are as described herein. The compound of the present application is an RIPK1 inhibitor, which can be used for treating an RIPK1-related disease.
Owner:ETERN THERAPEUTICS (WUXI) CO LTD

Light-emitting element, fused polycyclic compound for light-emitting element, and electronic device including light-emitting element

The invention relates to a light-emitting element, a fused polycyclic compound for the light-emitting element, and an electronic device including the light-emitting element. The light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission layer disposed between the first electrode and the second electrode and including a fused polycyclic compound represented by Formula 1 as a first compound. Formula 1
Owner:SAMSUNG DISPLAY CO LTD

Polycyclic compound as well as preparation method and medical application thereof

The invention relates to a polycyclic compound, a preparation method thereof and application of the polycyclic compound in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method of the polycyclic compound, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, especially application of the compound as a CCR4 inhibitor and application of the compound in preparation of drugs for treating and / or preventing CCR4-mediated or dependent diseases or symptoms. # imgabs0 #
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Organic electroluminescent material and device thereof

Disclosed are an organic electroluminescent material and a device thereof. The organic electroluminescent material is a polycyclic compound with a structure of formula 1, which can be used as a TADF material in an organic electroluminescent device. The polycyclic compound has a regulating effect on the emission color, can realize desired green light emission, has deeper HOMO and LUMO energy levels, has the potential to become an excellent light-emitting material, and has a very broad industrial application prospect. Also disclosed are an organic electroluminescent device comprising the compound and a compound composition comprising the compound.
Owner:BEIJING SUMMER SPROUT TECH CO LTD

Light emitting device and polycyclic compound for the same

A light emitting device of an embodiment includes a first electrode, a second electrode disposed on the first electrode, and at least one functional layer disposed between the first electrode and the second electrode. The at least one functional layer includes a polycyclic compound represented by Formula 1, thereby showing high emission efficiency properties and improved life characteristics.
Owner:SAMSUNG DISPLAY CO LTD

Light emitting element, fused polycyclic compound for the light emitting element, and display device including the light emitting element

A light emitting element includes a first electrode, a second electrode arranged on the first electrode, and an emission layer arranged between the first electrode and the second electrode and including a first compound represented by Formula 1.
Owner:SAMSUNG DISPLAY CO LTD

Pyridine polycyclic compound inhibitor, preparation method therefor and use thereof

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1

Pyrimidine derivative as well as preparation method and medical application thereof

The invention relates to a pyrimidine derivative, a preparation method thereof and application of the pyrimidine derivative in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method of the polycyclic compound, a pharmaceutical composition containing the pyrimidine derivative and application of the pharmaceutical composition as a therapeutic agent, especially application of the pharmaceutical composition as a BCL6 inhibitor or a degradation agent and application of the pharmaceutical composition in preparation of drugs for treating and / or preventing BCL6-mediated or dependent diseases or symptoms. Wherein each group in the general formula (I) is defined in the specification.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Polycyclic compound and organic light-emitting device including the same

Provided are a polycyclic compound represented by Formula 1 and an organic light-emitting device and an electronic apparatus, each including the same.
Owner:SAMSUNG DISPLAY CO LTD

Light emitting element, fused polycyclic compound for the same, and electronic apparatus including the same

Embodiments provide a fused polycyclic compound, a light emitting element that includes the fused polycyclic compound, and an electronic apparatus that includes the light emitting element. The light emitting element includes a first electrode, a second electrode disposed on the first electrode, and a light emitting layer disposed between the first electrode and the second electrode, wherein the light emitting layer includes the fused polycyclic compound. The fused polycyclic compound is represented by Formula 1, which is explained in the specification.
Owner:SAMSUNG DISPLAY CO LTD

Polycyclic compounds, light-emitting device, and electronic device

This application provides a light-emitting device. The light-emitting device includes a first electrode, a second electrode, and an emitting layer disposed between the first and second electrodes. The emitting layer comprises a polycyclic compound represented by Chemical Formula 1. Additionally, an electronic device including the light-emitting device and a polycyclic compound are also provided. Chemical Formula 1.
Owner:SAMSUNG DISPLAY CO LTD

Polycyclic Compounds that Inhibit H-PGDS

The present invention provides a compound having hematopoietic organ-type prostaglandin D synthase (H-PGDS) inhibitory activity and useful for the prevention and treatment of diseases involving the aforementioned enzyme, and a pharmaceutical composition comprising the compound. Specifically, there is provided a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), R 1 represents a hydrogen atom or the like, R 2 represents a hydrogen atom or the like, R 3 represents a hydrogen atom or the like, R 4 represents a hydrogen atom or the like, R 5 represents a hydrogen atom or the like, W represents an oxygen atom or the like, X represents C 1‑6 alkyl or the like.
Owner:SATO PHARMACEUTICAL CO LTD